法尼醇X受体在原发性胆汁性胆管炎治疗中的作用

Role of Farnesoid X Receptor in Treatment of Primary Biliary Cholangitis

原发性胆汁性胆管炎(PBC)是一种常见的胆汁淤积性肝病。熊去氧胆酸(UDCA)是目前惟一被批准并能有效治疗PBC的药物,但高达40%的PBC患者对UDCA应答不佳。法尼醇X受体(FXR)具有抑制胆汁酸合成、调控胆汁酸转运和抗肝纤维化的作用。本文就FXR在PBC治疗中的作用作一综述。

Primary biliary cholangitis （PBC） is a commonly seen cholestatic liver disease. Currently, ursodeoxy- cholic acid （UDCA） is the only drug approved for the effective treatment of PBC. However, up to 40% of PBC patients had poor response to UDCA. Farnesoid X receptor （FXR） can inhibit the synthesis of bile acid, regulating the transport of bile acid and playing a role in anti-hepatic fibrosis. This article reviewed the role of FXR in treatment of PBC.